Announcements Trials
Browse Landscape

Phase

Phase 2 121Phase NA 105Phase 1 78Phase 3 53Phase 1/2 43Phase EARLY_PHASE1 8Phase 4 4Phase 2/3 4

Status

Recruiting 25Completed 18Unknown 12Terminated 9Not yet recruiting 5Active not recruiting 4Withdrawn 2Enrolling by invitation 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 22Thoracic 11Breast 11Genitourinary 10Lymphoid 9Other hematologic neoplasm 7Head & Neck 7Sarcoma 4Gynecologic 4CNS 4Endocrine 3Dermatologic 3Tumor-Agnostic 2Myeloid 2Plasma cell 1Other solid neoplasm 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Hyperthermia 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

liposomal doxorubicin 2Doxorubicin 2olaparib 1cediranib 1atezolizumab 1Topotecan 1Taxes 1Paclitaxel 1NP-G2-044 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Gynecologic × Clear all
NCT02839707 2026-05-04

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
444 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02758951 2026-03-24

CAIRO6

Catharina Ziekenhuis Eindhoven

Phase 2/3 Active not recruiting
358 enrolled
GastrointestinalGynecologic

Hyperthermia, Colonic Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡